Back to search

Article

Adjuvant chemotherapy in T1a/bN0 breast cancer with a high 21-Gene Recurrence Score (>25): A 10-year follow-up in a real-world cohort

2024-10-14

Abstract excerpt

<title>Abstract</title> <p>Background In ER+/HER2- early breast cancer (BC), a 21-Gene Recurrence Score (RS) > 25 indicates a high-risk of distant-recurrence and a predictes benefit from adjuvant chemotherapy (aCT), independent of tumor size. However, T1a/b (≤ 1cm) node negative (N0) tumors, that are usually regarded clinically as of very low risk of recurrence, are under-represented in trials validating the pre...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
a857ba15-711b-5740-b564-de57cdc77238
DOI
10.21203/rs.3.rs-4892113/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Adjuvant chemotherapy in T1a/bN0 breast cancer with a high 21-Gene Recurrence Score (&gt;25): A 10-year follow-up in a real-world cohortDOI 10.21203/rs.3.rs-4892113/v1
Application of a 21-Gene Recurrence Score in a Swiss Single Center Breast Cancer Population. A Comparative Analysis of Treatment Administration before and after TAILORxSemantic proximity
Utilization and impact of 21-gene recurrence score assay for breast cancer in clinical practice across the United States: lessons learned from the 2010 to 2012 National Cancer Data Base analysis.Semantic proximity
Utilization and Outcomes of the 21-Gene Recurrence Score in pN2 Breast Cancer PatientsSemantic proximity
Detection of Disseminated Tumor Cells in Patients with Early Breast Cancer is Associated with 21-Gene-Assay: Results from the Impact of Recurrence Score ® Result on Adjuvant Treatment Decisions and Tumor Cell Dissemination in Estrogen Receptor-Positive and HER2-Negative Patients with Early Breast Cancer (IRMA) TrialSemantic proximity
The 21-Gene Recurrence Score in Clinically High Risk Lobular and Ductal Breast Cancer: A National Cancer Database StudySemantic proximity
Utility of the 21-Gene Recurrence Score in Node-Positive Breast Cancer.Semantic proximity
21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010-2013.Semantic proximity
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast CancerSemantic proximity
PreciseBreast is prognostic for breast cancer recurrence in a 21-gene assay managed cohortSemantic proximity
A nomogram to predict the high-risk RS in HR+/HER2-breast cancer patients older than 50 years of ageSemantic proximity
A 95-gene Signature Stratifies Recurrence Risk of Invasive Disease in ER-positive, HER2-negative, Node-negative Breast Cancer With Intermediate 21-gene Signature Recurrence ScoresSemantic proximity
Prospective Validation of a 21-Gene Expression Assay in Breast CancerSemantic proximity
Select a neighboring publication to make it the new centre.